Dextromethorphan Hydrobromide/Quinidine Sulfate

氢溴酸右美沙芬/硫酸奎尼丁

Report date: 2023/12/13 14:28:08

Base Information

Drug NameDextromethorphan Hydrobromide/Quinidine Sulfate
Drug Alias Name硫酸奎尼丁/氢溴酸右美沙芬deudextromethorphan hydrobromide/quinidine sulfatedeudextromethorphan hydrobromide+quinidine sulfatedeudextromethorphan hydrobromide + ultra-low dose quinidine sulfateDeudextromethorphan+Quinidine Sulfate +[9] 
ClassificationSmall molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonistsCytochrome P450 2D6 inhibitors
TargetsGlutamate [NMDA] receptorCytochrome P450 2D6
Therapy Area/IndicationsIrritable MoodPainDiabetic Neuropathies +[7] 
Global Approved IndicationsPseudobulbar PalsyNeurobehavioral Manifestations
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2010/10/29
Country/TerritoryUnited StatesEUMainland China
CombinationsYes Quinidine SulfateDextromethorphan Hydrobromide
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAvanir Pharma
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Kangchuanglian Biopharmaceutical Technology Research Co LtdCSPC Pharmaceutical Group LtdThe University Of Texas Health Science Center At Houston +[5] 
Inactive CompaniesJenson Pharmaceutical Services Ltd
Active IndicationsIrritable MoodPseudobulbar PalsyAmyotrophic Lateral Sclerosis +[4] 
Inactive IndicationsPainDiabetic NeuropathiesNeurobehavioral Manifestations

Other Information

ATC CodeN07XX59
Related LinksWikipediaKEGG